Gilead Sciences, Inc. is a global biopharmaceutical company focused on discovering, developing, and manufacturing antiviral and oncology therapies. Founded in 1987 and headquartered in Foster City, California, the company’s portfolio spans small-molecule drugs and biologics addressing HIV, viral hepatitis B and C, COVID‑19, and cancers. Gilead operates an international R&D and production network, carrying medicines from early discovery through process development and commercial supply.
Notable products include HIV regimens such as Biktarvy and Descovy; antiviral treatments for hepatitis C (e.g., Epclusa, Harvoni) and hepatitis B (e.g., Vemlidy); and the antiviral Veklury (remdesivir) for COVID‑19. In oncology, Gilead markets Trodelvy and, through its Kite subsidiary, autologous cell therapies including Yescarta and Tecartus for certain hematologic malignancies. The company’s activities are closely tied to chemical and bioprocess innovation, including active pharmaceutical ingredient (API) synthesis, formulation, and scale‑up to support global access and supply. Gilead is listed on the NASDAQ under the ticker GILD.
